Grant funding worth nearly €800,000 to develop antiviral awarded
France’s National Research Agency (ANR) and Defense Innovation Agency (AID) will finance the BUNYANTIVIR project to introduce a novel therapeutic approach for Bunyaviricetes’ class of human pathogenic viruses found in tropical and subtropical regions.
The BUNYANTIVIR project has been selected under the call for proposals for the 2024 ASTRID Maturation programme, designed to support the development of scientific work carried out under other research support schemes that have received financial support from France’s Ministry of Armed Forces.
The programme aims to advance into the antiviral development pipeline a series of “hit” compounds that have been biophysically characterised by microscale thermophoresis (MST) and differential scanning fluorimetry (DSF). Their inhibition was evaluated in vitro and in cell cultures infected with several viruses. Several high-affinity ligands have demonstrated in vitro efficacy on the target enzyme and in infected cells. This provides an optimal basis for the next steps in the development of more specific and more active compounds.
BUNYANTIVIR was set up with a number of academic partners: the Biological Macromolecule Architecture and Function Laboratory (AFMB) and the Emerging Viruses Unit (UVE) in Marseille, France, together with the Emerging Viral Infections Biology Unit (UBIVE) at Lyon’s Institut Pasteur. ASTRID Maturation was launched by France’s ANR in partnership with the AID.
Future of BUNYANTIVIR
With a budget of nearly €800,000 over three years, BUNYANTIVIR aims to progress the preclinical development of a novel antiviral. This involves selecting a series of ‘hit’ compounds whose inhibitory actions have been evaluated in vitro and in cell cultures infected with different viruses. Several high-affinity ligands have shown in vitro efficacy on the target enzyme and infected cells. The ultimate objective is to identify the most relevant drug candidates.
This project is possible thanks to the knowledge, multidisciplinary nature, collaboration and complementary skills of the four partners, who are experts in chemistry, biochemistry, crystallography and virology. For instance, Oxeltis is responsible for synthesising the inhibitors, co‑designed with the AFMB team, and for optimising the initial hits. Once one or more leads have been selected, Oxeltis will scale up production to supply the quantities needed for in vivo testing in rodents, then in an animal infection model. This initial stage is expected to take place within 18 to 24 months.
“This programme aims to inhibit an origin recognition replication complex in Bunyaviricetes, and to develop a novel therapeutic approach for certain dangerous viruses in this class affecting humans, such as Crimean-Congo hemorrhagic fever (Nairoviridae) and Lassa fever (Arenaviridae),” said Jean‑Marc Allaire, CEO of Oxeltis.
During the project, the partners will benefit from hits and leads rational optimisation, stability studies, structural biology data, in vitro evaluations in cell models and pharmacokinetics studies; lastly, the potential candidates will be evaluated in vitro.
Karine Alvarez, scientific coordinator for the project at AFMB, said: “This project provides us with the opportunity to target an under-researched viral recognition complex. By leveraging our knowledge in structural biology, particularly X-ray crystallography, we aim to shed light on ligand interactions with viral enzymes, to provide a rational direction for inhibitor optimization. This interdisciplinary collaboration is essential for developing novel antiviral candidates for Bunyaviricetes.”
Megan Thomas, Multimedia Editor, DDW
